Showing 3571-3580 of 3610 results for "".
Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicASLMS New Beginnings Initiative
https://practicaldermatology.com/series/the-practical-dermatology-podcast/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeThe Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/series/the-practical-dermatology-podcast/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloTime Is Hair: An Update on the Diagnosis and Treatment of Scarring Alopecias in Patients with Darker Skin Tones
https://practicaldermatology.com/series/the-practical-dermatology-podcast/time-is-hair-an-update-on-the-diagnosis-and-treatment-of-scarring-alopecia-in-patients-with-darker-skin-tones/18198/In part two of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Dr. Andrew Alexis, a dermatologist from New York City and the President of the Skin of Color Society; Dr. Corey Hartman, a dermatologist in Birmingham, Alabama; and Dr. Janiene Luke, a dermatoloPreventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/Are you as excited as our experts are about immunotherapy for the adjuvant treatment of stage IIB/IIC melanoma? Tune in to find out why you should be!DermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiDermWireTV: Ped Derm Salaries; Skin Cancer Symposium Kicks Off; Pandemic Self Care Stats
https://practicaldermatology.com/topics/practice-management/dermwiretv-ped-derm-salaries-skin-cancer-symposium-kicks-off-pandemic-self-care-stats/19910/According to the Society for Pediatric Dermatology’s 2020 Pediatric Dermatology Physician Compensation Report, salaries have increased 37% since 2014. Pediatric dermatologist Mercedes Gonzalez, MD comments. The inaugural Skin Cancer Symposium is underway and the Symposium for Inflammatory Disease kiDermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketTargeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
https://practicaldermatology.com/programs/cme/targeting-il-13-in-moderate-to-severe-atopic-dermatitis-forging-a-new-path-to-improved-disease-and-patient-outcomes/16384/Get expert insights on incorporating novel agents to optimize care for patients with atopic dermatitis, including those targeting interleukin (IL)-13.The Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and c